Status:
COMPLETED
Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting
Lead Sponsor:
Jinling Hospital, China
Collaborating Sponsors:
CSPC-NBP Pharmaceutical Co., Ltd.
Conditions:
Restenosis
Eligibility:
All Genders
40-85 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether butylphthalide are effective for Preventing Restenosis after Intracranial and Extracranial Artery Stenting
Detailed Description
Ischemic stroke is a significant cause of death, most of the patients is caused by atherosclerosis,current treatments include internal medicine medications, interventional treatment and so on,among th...
Eligibility Criteria
Inclusion
- . DSA check to be sure, the VA, BA ICA, MCA, PCA and other major blood vessels, have corresponding stenosis of symptoms more than 50%, not corresponding symptoms stenosis of greater than 70%;
- . A successful cerebrovascular carotid stenting noted.
Exclusion
- . There is a serious bleeding tendency, nearly three months have intracranial bleeding or cranial out blood;
- . Active peptic ulcer;
- . Not good control high blood pressure; the wickedness of
- . Blood vessel distortion, variation, narrow degree badly, can not be implemented stents operation;
- . Serious cardiopulmonary etc medical problems;
- . Those allergic to celery;
- . Contrast agents allergy;
- . Can't complete follow-up.
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01405248
Start Date
July 1 2011
End Date
January 1 2014
Last Update
October 26 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology ;Jinling Hospital
Nanjing, Jiangsu, China, 210002